|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
|
JP4794301B2
(ja)
*
|
2003-06-11 |
2011-10-19 |
中外製薬株式会社 |
抗体の製造方法
|
|
AU2006232287B2
(en)
*
|
2005-03-31 |
2011-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for producing polypeptides by regulating polypeptide association
|
|
RU2423381C2
(ru)
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
PT1999154E
(pt)
*
|
2006-03-24 |
2013-01-24 |
Merck Patent Gmbh |
Domínios proteicos heterodiméricos modificados
|
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
CL2007002404A1
(es)
*
|
2006-08-21 |
2008-04-18 |
Hoffmann La Roche |
Uso de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular) para el tratamiento de un paciente que padece una recaida de cancer her2 positivo durante o despues del tratamiento con un anticuerpo anti-her2.
|
|
DK2066694T3
(en)
|
2006-09-29 |
2016-02-08 |
Oncomed Pharm Inc |
Compositions and Methods for Diagnosing and Treating Cancer
|
|
US9062097B2
(en)
*
|
2007-08-21 |
2015-06-23 |
Morpho Sys AG |
Methods for the formation of disulphide bonds
|
|
ES2595638T3
(es)
*
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
|
EP2080770A1
(en)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
|
JP5717624B2
(ja)
|
2009-03-19 |
2015-05-13 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
EP2826789A1
(en)
|
2009-03-19 |
2015-01-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
|
WO2010129304A2
(en)
|
2009-04-27 |
2010-11-11 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
US10150808B2
(en)
|
2009-09-24 |
2018-12-11 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant regions
|
|
US9109216B2
(en)
|
2009-09-24 |
2015-08-18 |
Ucb Pharma, S.A. |
Bacterial host strain
|
|
HUE029661T2
(en)
|
2009-10-16 |
2017-03-28 |
Oncomed Pharm Inc |
A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
|
|
GB201000590D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial host strain
|
|
GB201000587D0
(en)
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
GB201000591D0
(en)
*
|
2010-01-14 |
2010-03-03 |
Ucb Pharma Sa |
Bacterial hoist strain
|
|
EP2533811A4
(en)
*
|
2010-02-12 |
2013-12-25 |
Res Corp Technologies Inc |
MULTIMETER PROTEINS WITH IMMUNE LOBULIN CONSTANTS DOMAINS
|
|
WO2011108714A1
(ja)
|
2010-03-04 |
2011-09-09 |
中外製薬株式会社 |
抗体定常領域改変体
|
|
KR101860963B1
(ko)
*
|
2010-04-23 |
2018-05-24 |
제넨테크, 인크. |
이종다량체 단백질의 생산
|
|
GB201012599D0
(en)
|
2010-07-27 |
2010-09-08 |
Ucb Pharma Sa |
Process for purifying proteins
|
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
|
TWI452136B
(zh)
|
2010-11-17 |
2014-09-11 |
中外製藥股份有限公司 |
A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
PT3434767T
(pt)
|
2010-11-30 |
2026-01-23 |
Chugai Pharmaceutical Co Ltd |
Agente terapêutico indutor de citotoxicidade
|
|
US10689447B2
(en)
*
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
|
RU2018108836A
(ru)
*
|
2011-02-04 |
2019-03-14 |
Дженентек, Инк. |
ВАРИАНТЫ Fc И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
|
|
EP2714738B1
(en)
|
2011-05-24 |
2018-10-10 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
|
HRP20180226T1
(hr)
*
|
2011-07-13 |
2018-03-09 |
Ucb Biopharma Sprl |
Bakterijski soj domaćina koji eksprimira rekombinantnu dsbc
|
|
LT3485903T
(lt)
|
2011-09-23 |
2023-02-27 |
Mereo Biopharma 5, Inc. |
Vegf/ dll4 surišantys agentai ir jų panaudojimas
|
|
RU2654567C2
(ru)
*
|
2011-10-11 |
2018-05-21 |
Дженентек, Инк. |
Улучшенная сборка биспецифических антител
|
|
CN109134658B
(zh)
|
2011-10-31 |
2022-10-14 |
中外制药株式会社 |
控制了重链与轻链的缔合的抗原结合分子
|
|
US9248181B2
(en)
|
2012-04-20 |
2016-02-02 |
Merus B.V. |
Methods and means for the production of Ig-like molecules
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
HUE042040T2
(hu)
|
2012-09-27 |
2019-06-28 |
Merus Nv |
Bispecifikus IGG antitestek mint T-sejt kapcsolók
|
|
US9599620B2
(en)
|
2012-10-31 |
2017-03-21 |
Oncomed Pharmaceuticals, Inc. |
Methods and monitoring of treatment with a DLL4 antagonist
|
|
CN104903349B
(zh)
|
2012-11-08 |
2018-10-19 |
十一生物治疗股份有限公司 |
Il-6拮抗剂及其应用
|
|
CN105051528A
(zh)
*
|
2012-11-15 |
2015-11-11 |
弗·哈夫曼-拉罗切有限公司 |
离子强度介导的pH梯度离子交换色谱
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
MX361088B
(es)
|
2012-11-21 |
2018-11-26 |
Janssen Biotech Inc |
Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
|
|
US10150800B2
(en)
|
2013-03-15 |
2018-12-11 |
Zyngenia, Inc. |
EGFR-binding modular recognition domains
|
|
CA2919076C
(en)
*
|
2013-07-31 |
2024-01-30 |
Amgen Inc. |
Stabilization of fc-containing polypeptides
|
|
ES2881306T3
(es)
|
2013-09-27 |
2021-11-29 |
Chugai Pharmaceutical Co Ltd |
Método para la producción de heteromultímeros de polipéptidos
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
JP6771385B2
(ja)
|
2014-02-28 |
2020-10-21 |
メルス ナムローゼ フェンノートシャップ |
二重特異性抗体および医薬組成物
|
|
WO2015130173A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibody that binds erbb-2 and erbb-3
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
BR122021009041B1
(pt)
|
2014-05-06 |
2022-11-29 |
Genentech, Inc |
Métodos para a preparação de uma proteína heteromultimérica
|
|
WO2016001810A1
(en)
|
2014-07-01 |
2016-01-07 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
MA40609B1
(fr)
|
2014-09-05 |
2020-05-29 |
Janssen Pharmaceutica Nv |
Agents de liaison cd123 et leurs utilisations
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
|
WO2016073791A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
US10066002B2
(en)
*
|
2014-11-05 |
2018-09-04 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
|
JP6594438B2
(ja)
|
2014-11-07 |
2019-10-23 |
セセン バイオ， インコーポレイテッド |
改善されたｉｌ−６抗体
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP7082484B2
(ja)
*
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
EP3291836A4
(en)
|
2015-05-06 |
2018-11-14 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
|
US9914777B2
(en)
|
2015-07-10 |
2018-03-13 |
Merus N.V. |
Human CD3 binding antibody
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
MX2018002043A
(es)
|
2015-08-17 |
2018-07-06 |
Janssen Pharmaceutica Nv |
ANTICUERPOS ANTI-BCMA, MOLíCULAS DE UNIíN A ANTíGENOS BIESPECíFICAS QUE SE UNEN A BCMA Y CD3, Y USOS DE ESTOS.
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
US11339213B2
(en)
|
2015-09-23 |
2022-05-24 |
Mereo Biopharma 5, Inc. |
Methods and compositions for treatment of cancer
|
|
BR112018006251A2
(pt)
|
2015-09-30 |
2018-10-16 |
Janssen Biotech Inc |
anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
|
|
SMT202100230T1
(it)
|
2015-10-23 |
2021-07-12 |
Fundacio Inst De Recerca Biomedica Irb Barcelona |
Molecole di legame che inibiscono la crescita tumorale
|
|
EA201891084A1
(ru)
|
2015-11-02 |
2019-10-31 |
|
Антитела к il1rap, биспецифические антигенсвязывающие молекулы, которые связываются с il1rap и cd3, и их применение
|
|
PE20181326A1
(es)
|
2015-11-03 |
2018-08-20 |
Janssen Biotech Inc |
Anticuerpos que se unen especificamente a pd-1 y sus usos
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
AU2016381992B2
(en)
|
2015-12-28 |
2024-01-04 |
Chugai Seiyaku Kabushiki Kaisha |
Method for promoting efficiency of purification of Fc region-containing polypeptide
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
CN108718522A
(zh)
|
2016-02-23 |
2018-10-30 |
赛森生物股份有限公司 |
Il-6拮抗剂制剂及其用途
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
US11072666B2
(en)
|
2016-03-14 |
2021-07-27 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
CR20180554A
(es)
|
2016-04-28 |
2019-01-10 |
Chugai Pharmaceutical Co Ltd |
Preparaciones que contienen anticuerpos
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
WO2018031400A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
|
|
WO2018031258A1
(en)
|
2016-08-12 |
2018-02-15 |
Janssen Biotech, Inc. |
Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
JOP20190095A1
(ar)
|
2016-10-27 |
2019-04-28 |
Janssen Pharmaceutica Nv |
مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
|
|
CN110300599B
(zh)
|
2016-12-07 |
2024-07-02 |
艾吉纳斯公司 |
抗体和其使用方法
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
CN110461358A
(zh)
|
2017-03-31 |
2019-11-15 |
公立大学法人奈良县立医科大学 |
可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
|
|
IL269656B2
(en)
|
2017-03-31 |
2024-06-01 |
Merus Nv |
Bispecific antibodies that bind ERBB-2 and ERBB3 for use in the treatment of cells with NRG1 fusion gene
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
JP7296891B2
(ja)
|
2017-05-17 |
2023-06-23 |
メルス ナムローゼ フェンノートシャップ |
乳癌のためのＥｒｂＢ－２／ＥｒｂＢ－３二重特異性抗体と内分泌療法との組み合わせ
|
|
MX2019014572A
(es)
|
2017-06-05 |
2020-07-29 |
Janssen Biotech Inc |
Métodos de ingeniería de carga superficial para la producción de anticuerpos biespecíficos.
|
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
|
AR112257A1
(es)
|
2017-06-21 |
2019-10-09 |
Gilead Sciences Inc |
Anticuerpos multiespecíficos dirigidos al vih-1 gp120 y cd3 humana, composiciones que los comprende, ácido nucleico, vector y célula huésped relacionados, método para producirlos, método para detectar células que expresan gp120 y cd3, kit de anticuerpos, fragmentos de anticuerpo que se une a gp120 y método para producirlos
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
SG11202001050PA
(en)
|
2017-08-09 |
2020-03-30 |
Merus Nv |
Antibodies that bind egfr and cmet
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
CN119161488A
(zh)
|
2017-11-01 |
2024-12-20 |
中外制药株式会社 |
具有降低的生物活性的抗体变体和同种型
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
UA130542C2
(uk)
|
2018-05-16 |
2026-03-18 |
Янссен Байотек, Інк. |
Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
MA52772A
(fr)
|
2018-05-24 |
2021-04-14 |
Janssen Biotech Inc |
Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations
|
|
CA3101271A1
(en)
|
2018-05-24 |
2019-11-28 |
Janssen Biotech, Inc. |
Anti-cd3 antibodies and uses thereof
|
|
PE20211916A1
(es)
|
2018-05-24 |
2021-09-28 |
Janssen Biotech Inc |
Agentes aglutinantes del psma y usos de estos
|
|
JOP20190116A1
(ar)
|
2018-05-24 |
2019-11-24 |
Janssen Biotech Inc |
الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
KR102870868B1
(ko)
|
2018-06-01 |
2025-10-15 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN112654394B
(zh)
|
2018-06-19 |
2025-07-11 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
DK4257600T3
(da)
|
2018-07-03 |
2025-05-26 |
Gilead Sciences Inc |
Antistoffer rettet mod hiv gp120 og fremgangsmåder til at bruge dem
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
US20210380684A1
(en)
*
|
2018-09-28 |
2021-12-09 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
|
JP7689074B2
(ja)
|
2019-01-15 |
2025-06-05 |
ヤンセン バイオテツク，インコーポレーテツド |
若年性特発性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
|
|
WO2020152544A1
(en)
|
2019-01-23 |
2020-07-30 |
Janssen Biotech, Inc. |
Anti-tnf antibody compositions for use in methods for the treatment of psoriatic arthritis
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
BR112021016149A2
(pt)
|
2019-02-26 |
2021-10-13 |
Janssen Biotech, Inc. |
Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
|
|
MX2021010857A
(es)
|
2019-03-11 |
2021-12-15 |
Janssen Biotech Inc |
Anticuerpos biespecificos anti-v(beta17)/anti-cd123.
|
|
EA202192505A1
(ru)
|
2019-03-14 |
2022-03-29 |
Янссен Байотек, Инк. |
Способы получения композиций антитела к фно
|
|
EP3938384A4
(en)
|
2019-03-14 |
2022-12-28 |
Janssen Biotech, Inc. |
PREPARATION PROCEDURES FOR THE PREPARATION OF ANTI-IL12/IL23 ANTIBODY COMPOSITIONS
|
|
KR20210141998A
(ko)
|
2019-03-14 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-tnf 항체 조성물의 제조 방법
|
|
WO2020183269A1
(en)
|
2019-03-14 |
2020-09-17 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
BR112021019337A2
(pt)
|
2019-03-29 |
2021-12-07 |
Atarga Llc |
Anticorpo anti-fgf23
|
|
US11591395B2
(en)
|
2019-04-19 |
2023-02-28 |
Janssen Biotech, Inc. |
Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
|
|
MA55903A
(fr)
|
2019-05-08 |
2022-03-16 |
Janssen Biotech Inc |
Matières et méthodes pour moduler l'immunité médiée par les lymphocytes t
|
|
US11850248B2
(en)
|
2019-05-14 |
2023-12-26 |
Yuhan Corporation |
Therapies with 3rd generation EGFR tyrosine kinase inhibitors
|
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
|
CN118994397A
(zh)
|
2019-05-21 |
2024-11-22 |
诺华股份有限公司 |
针对bcma的三特异性结合分子及其用途
|
|
US12037378B2
(en)
|
2019-05-21 |
2024-07-16 |
Novartis Ag |
Variant CD58 domains and uses thereof
|
|
JP7489407B2
(ja)
|
2019-05-21 |
2024-05-23 |
ノバルティス アーゲー |
Ｃｄ１９結合分子及びその使用
|
|
JP7500619B2
(ja)
|
2019-05-30 |
2024-06-17 |
アムジエン・インコーポレーテツド |
抗体の二量体化を促進するためのヒンジ領域の操作
|
|
JP2022536279A
(ja)
|
2019-06-03 |
2022-08-15 |
ヤンセン バイオテツク，インコーポレーテツド |
乾癬性関節炎を治療するための抗ｔｎｆ抗体組成物及び方法
|
|
CA3147044A1
(en)
|
2019-07-11 |
2021-01-14 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Agents that interfere with thymic stromal lymphopoietin (tslp)-receptor signaling
|
|
MX2022000496A
(es)
|
2019-07-12 |
2022-04-20 |
Janssen Pharmaceutica Nv |
Agentes de unión y usos de estos.
|
|
BR112022002067A2
(pt)
|
2019-08-08 |
2022-06-14 |
Regeneron Pharma |
Formatos de molécula de ligação ao antígeno
|
|
US20220242962A1
(en)
|
2019-08-12 |
2022-08-04 |
Aptevo Research And Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
|
WO2021057991A1
(zh)
|
2019-09-29 |
2021-04-01 |
北京加科思新药研发有限公司 |
对lif具有特异性的结合分子及其用途
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
MX2022005330A
(es)
|
2019-11-05 |
2022-05-26 |
Regeneron Pharma |
Moleculas de union multiespecificas con scfv en el extremo nterminal.
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
CA3164226A1
(en)
|
2019-12-11 |
2021-06-17 |
Cilag Gmbh International |
Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
WO2021127487A2
(en)
|
2019-12-20 |
2021-06-24 |
Regeneron Pharmaceuticals, Inc. |
Novel il2 agonists and methods of use thereof
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
JP2023509195A
(ja)
|
2020-01-08 |
2023-03-07 |
アルジェニクス ビーブイ |
天疱瘡症を治療する方法
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
JP7783182B2
(ja)
|
2020-02-12 |
2025-12-09 |
ヤンセン バイオテツク，インコーポレーテツド |
ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
US20230128499A1
(en)
|
2020-03-27 |
2023-04-27 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune diseases
|
|
AU2021249888A1
(en)
*
|
2020-04-01 |
2022-10-27 |
Kyowa Kirin Co., Ltd. |
Antibody composition
|
|
WO2021209953A1
(en)
|
2020-04-16 |
2021-10-21 |
Janssen Biotech, Inc. |
Systems, materials, and methods for reversed-phase high performance liquid chromatography (rp-hplc) for monitoring formation of multi-specific molecules
|
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
|
JP2023524875A
(ja)
|
2020-05-11 |
2023-06-13 |
ヤンセン バイオテツク，インコーポレーテツド |
多発性骨髄腫を治療するための方法
|
|
WO2021231447A1
(en)
|
2020-05-12 |
2021-11-18 |
Regeneron Pharmaceuticals, Inc. |
Novel il10 agonists and methods of use thereof
|
|
CN116249714A
(zh)
|
2020-05-27 |
2023-06-09 |
詹森生物科技公司 |
包含cd3抗原结合结构域的蛋白质及其用途
|
|
GB202008860D0
(en)
|
2020-06-11 |
2020-07-29 |
Univ Oxford Innovation Ltd |
BTLA antibodies
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
JP2023537470A
(ja)
|
2020-08-03 |
2023-09-01 |
ヤンセン バイオテツク，インコーポレーテツド |
ウイルス治療における多方向バイオ輸送のための材料及び方法
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CA3190987A1
(en)
|
2020-08-10 |
2022-02-17 |
Janssen Biotech, Inc. |
Materials and methods for producing bioengineered virus specific lymphocytes
|
|
US20230322955A1
(en)
|
2020-08-20 |
2023-10-12 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
|
CN116194141A
(zh)
|
2020-08-25 |
2023-05-30 |
詹森生物科技公司 |
具有egfr突变的非小细胞肺癌的治疗
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
TW202227495A
(zh)
|
2020-09-11 |
2022-07-16 |
美商健生生物科技公司 |
用於調節β鏈介導之免疫的方法及組成物
|
|
WO2022056197A1
(en)
|
2020-09-11 |
2022-03-17 |
Janssen Biotech, Inc. |
Immune targeting molecules and uses thereof
|
|
WO2022072291A1
(en)
*
|
2020-09-30 |
2022-04-07 |
Amgen Inc. |
Cation exchange chromatography process
|
|
US20230374162A1
(en)
|
2020-10-07 |
2023-11-23 |
Amgen Inc. |
Rational selection of building blocks for the assembly of multispecific antibodies
|
|
TW202231292A
(zh)
|
2020-10-13 |
2022-08-16 |
美商健生生物科技公司 |
用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
|
|
EP4237003A4
(en)
|
2020-10-28 |
2025-07-09 |
Janssen Biotech Inc |
COMPOSITIONS AND METHODS FOR MODULATING GAMMA DELTA CHAIN-MEDIATED IMMUNITY
|
|
IL302412A
(en)
|
2020-11-06 |
2023-06-01 |
Novartis Ag |
Anti-CD19 and B-cell targeting agent combination therapy for the treatment of B-cell malignancies
|
|
CA3199095A1
(en)
|
2020-11-06 |
2022-05-12 |
Novartis Ag |
Cd19 binding molecules and uses thereof
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
IL303328A
(en)
|
2020-12-01 |
2023-07-01 |
Aptevo Res & Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
|
EP4284838A2
(en)
|
2021-01-28 |
2023-12-06 |
Janssen Biotech, Inc. |
Psma binding proteins and uses thereof
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
JP2024507180A
(ja)
|
2021-02-16 |
2024-02-16 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
|
|
BR112023016360A2
(pt)
|
2021-02-16 |
2024-01-23 |
Janssen Biotech Inc |
Materiais e métodos para determinação aprimorada de ligante alvo
|
|
BR112023018278A2
(pt)
|
2021-03-09 |
2023-10-31 |
Janssen Biotech Inc |
Tratamento de cânceres sem mutações de ativação de egfr
|
|
JP7714675B2
(ja)
|
2021-03-24 |
2025-07-29 |
ヤンセン バイオテツク，インコーポレーテツド |
ＣＤ７９ｂ、ＣＤ２０、及びＣＤ３を標的とする三重特異性抗体
|
|
CN117098781A
(zh)
|
2021-03-24 |
2023-11-21 |
詹森生物科技公司 |
靶向cd22和cd79b的抗体
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
|
CA3219609A1
(en)
|
2021-05-04 |
2022-11-10 |
Regeneron Pharmaceuticals, Inc. |
Multispecific fgf21 receptor agonists and their uses
|
|
TW202309094A
(zh)
|
2021-05-18 |
2023-03-01 |
美商健生生物科技公司 |
用於識別癌症患者以進行組合治療之方法
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
JP2024522360A
(ja)
|
2021-06-04 |
2024-06-18 |
アムジエン・インコーポレーテツド |
抗ｃｃｒ８抗体及びその使用
|
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
|
EP4355786A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
|
|
WO2022269451A1
(en)
|
2021-06-22 |
2022-12-29 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
|
US12534524B2
(en)
|
2021-07-09 |
2026-01-27 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-TNF antibody compositions
|
|
JP2024527581A
(ja)
|
2021-07-09 |
2024-07-25 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｉｌ１２／ｉｌ２３抗体組成物を生産するための製造方法
|
|
EP4367136A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-tnf antibody compositions
|
|
AU2022314734A1
(en)
|
2021-07-19 |
2024-02-08 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
|
US20250270314A1
(en)
|
2021-08-02 |
2025-08-28 |
Tavotek Biotech (Suzhou) Ltd |
Anti-cdh17 monoclonal and bispecific antibodies and uses thereof
|
|
US20250277051A1
(en)
|
2021-08-02 |
2025-09-04 |
Hangzhou Unogen Biotech, Ltd |
Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof
|
|
KR20240046251A
(ko)
|
2021-08-16 |
2024-04-08 |
리제너론 파아마슈티컬스, 인크. |
신규 il27 수용체 효능제 및 그의 사용 방법
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3232216A1
(en)
|
2021-10-18 |
2023-04-27 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Anti-egfr antibodies, anti-cmet antibodies, anti-vegf antibodies, multispecific antibodies, and uses thereof
|
|
CN118119642A
(zh)
|
2021-10-28 |
2024-05-31 |
诺华股份有限公司 |
工程化Fc变体
|
|
JP2024543019A
(ja)
|
2021-11-01 |
2024-11-19 |
ヤンセン バイオテツク，インコーポレーテツド |
β鎖媒介免疫を調節するための組成物及び方法
|
|
MX2024005392A
(es)
|
2021-11-03 |
2024-08-06 |
Janssen Biotech Inc |
Métodos para tratar cánceres y potenciar la eficacia de anticuerpos biespecíficos para bcmaxcd3.
|
|
KR20240099460A
(ko)
|
2021-11-11 |
2024-06-28 |
리제너론 파아마슈티컬스, 인크. |
Cd20-pd1 결합 분자 및 이의 사용 방법
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
US20230183360A1
(en)
|
2021-12-09 |
2023-06-15 |
Janssen Biotech, Inc. |
Use of Amivantamab to Treat Colorectal Cancer
|
|
AU2023208426A1
(en)
|
2022-01-24 |
2024-07-25 |
Novimmune Sa |
Composition and methods for the selective activation of cytokine signaling pathways
|
|
TW202342057A
(zh)
|
2022-02-07 |
2023-11-01 |
美商健生生物科技公司 |
用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
IL314916A
(en)
|
2022-03-07 |
2024-10-01 |
Novimmune Sa |
Bispecific CD28 antibodies for targeted T cell activation
|
|
EP4493592A1
(en)
|
2022-03-14 |
2025-01-22 |
LamKap Bio gamma AG |
Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
|
|
EP4499683A1
(en)
|
2022-03-29 |
2025-02-05 |
NGM Biopharmaceuticals, Inc. |
Ilt3 and cd3 binding agents and methods of use thereof
|
|
IL316174A
(en)
|
2022-04-26 |
2024-12-01 |
Novartis Ag |
Multiple specific antibodies targeting IL-13 and IL-18
|
|
KR20250024872A
(ko)
|
2022-05-11 |
2025-02-19 |
리제너론 파마슈티칼스 인코포레이티드 |
다중특이적 결합 분자 전구단백질 및 이의 용도
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
CA3257348A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
CA3258187A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
INTERLEUKIN-2 PROPROTEINS AND THEIR USES
|
|
CN119698429A
(zh)
|
2022-06-15 |
2025-03-25 |
阿根思有限公司 |
Fcrn结合分子及使用方法
|
|
WO2024003837A1
(en)
|
2022-06-30 |
2024-01-04 |
Janssen Biotech, Inc. |
Use of anti-egfr/anti-met antibody to treat gastric or esophageal cancer
|
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
CN119497721A
(zh)
|
2022-07-29 |
2025-02-21 |
艾莱克特有限责任公司 |
转铁蛋白受体抗原结合结构域及其用途
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
CN120051483A
(zh)
|
2022-08-18 |
2025-05-27 |
再生元制药公司 |
干扰素前蛋白及其用途
|
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
|
US20240254234A1
(en)
|
2022-10-21 |
2024-08-01 |
Novimmune Sa |
PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
|
|
IL318765A
(en)
|
2022-10-24 |
2025-04-01 |
Hoffmann La Roche |
Predicting response to IL-6 antagonists
|
|
WO2024089551A1
(en)
|
2022-10-25 |
2024-05-02 |
Janssen Biotech, Inc. |
Msln and cd3 binding agents and methods of use thereof
|
|
EP4634220A2
(en)
|
2022-12-16 |
2025-10-22 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses
|
|
US20240252601A1
(en)
|
2022-12-23 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Ace2 fusion proteins and uses thereof
|
|
KR20250148746A
(ko)
|
2023-01-13 |
2025-10-14 |
리제너론 파아마슈티컬스, 인크. |
Fgfr3 결합 분자 및 그의 사용 방법
|
|
IL322055A
(en)
|
2023-01-13 |
2025-09-01 |
Regeneron Pharma |
IL12 receptor agonists and methods of using them
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
EP4662239A1
(en)
|
2023-02-09 |
2025-12-17 |
Janssen Biotech, Inc. |
Anti-v beta 17/anti-cd123 bispecific antibodies
|
|
JP2026507123A
(ja)
|
2023-02-28 |
2026-02-27 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｔ細胞活性化剤およびその使用方法
|
|
CN121057744A
(zh)
|
2023-02-28 |
2025-12-02 |
再生元制药公司 |
多价抗刺突蛋白结合分子及其用途
|
|
WO2024189544A1
(en)
|
2023-03-13 |
2024-09-19 |
Janssen Biotech, Inc. |
Combination therapies with bi-specific anti-egfr/c-met antibodies and anti-pd-1 antibodies
|
|
WO2024194685A2
(en)
|
2023-03-17 |
2024-09-26 |
Oxitope Pharma B.V. |
Anti-phosphocholine antibodies and methods of use thereof
|
|
KR20250173600A
(ko)
|
2023-03-17 |
2025-12-10 |
옥시토프 파마 비.브이. |
항-포스포콜린 항체 및 그 사용 방법
|
|
EP4709756A1
(en)
|
2023-05-10 |
2026-03-18 |
Regeneron Pharmaceuticals, Inc. |
Cd20-pd1 binding molecules and methods of use thereof
|
|
CN121752592A
(zh)
|
2023-05-12 |
2026-03-27 |
再生元制药公司 |
干扰素受体拮抗剂及其用途
|
|
CA3228195A1
(en)
|
2023-05-23 |
2025-06-30 |
Janssen Biotech, Inc. |
Methods for treatment of non-small cell lung cancer (nsclc)
|
|
EP4724477A1
(en)
|
2023-06-11 |
2026-04-15 |
Regeneron Pharmaceuticals, Inc. |
Circularized antibody molecules
|
|
CN119143869A
(zh)
|
2023-06-16 |
2024-12-17 |
复旦大学 |
乙肝病毒表面抗体及其应用
|
|
IL326401A
(en)
|
2023-08-07 |
2026-04-01 |
Janssen Biotech Inc |
Stabilized CD3 antigen binding materials and methods of using them
|
|
AU2024319838A1
(en)
|
2023-08-07 |
2025-02-13 |
Janssen Biotech, Inc. |
Enpp3 and cd3 binding agents and methods of use thereof
|
|
WO2025038600A1
(en)
|
2023-08-14 |
2025-02-20 |
Amgen Inc. |
Methods for reducing yellow color
|
|
EP4630457A1
(en)
|
2023-08-18 |
2025-10-15 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules and uses thereof
|
|
WO2025049343A1
(en)
|
2023-08-25 |
2025-03-06 |
Proteologix Us Inc. |
Anti-tslp antibody constructs and uses thereof
|
|
AU2024334289A1
(en)
|
2023-08-25 |
2026-04-09 |
Proteologix Us Inc. |
Anti-il-13 multispecific antibody constructs and uses thereof
|
|
AU2024337472A1
(en)
|
2023-09-05 |
2026-04-16 |
Janssen Biotech, Inc. |
Methods of treating non-small cell lung cancer
|
|
WO2025051895A1
(en)
|
2023-09-06 |
2025-03-13 |
Novimmune Sa |
Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
|
|
US20250101111A1
(en)
|
2023-09-07 |
2025-03-27 |
argenx BV |
Fcrn antagonists and methods of use
|
|
WO2025068957A1
(en)
|
2023-09-29 |
2025-04-03 |
Novartis Ag |
Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
|
|
WO2025079020A1
(en)
|
2023-10-12 |
2025-04-17 |
Janssen Biotech, Inc. |
First line treatment in egfr exon 20 insertion-mutated advanced non-small cell lung cancer
|
|
WO2025085610A1
(en)
|
2023-10-18 |
2025-04-24 |
Janssen Biotech, Inc. |
Combination treatment of prostate cancers with two bispecific antibodies
|
|
WO2025094087A1
(en)
|
2023-10-30 |
2025-05-08 |
Johnson & Johnson Enterprise Innovation Inc. |
Safe administration of a2a rector antagonist
|
|
WO2025106469A1
(en)
|
2023-11-14 |
2025-05-22 |
Regeneron Pharmaceuticals, Inc. |
Engineered heavy chain variable domains and uses thereof
|
|
WO2025122614A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
WO2025120583A2
(en)
|
2023-12-08 |
2025-06-12 |
Janssen Biotech, Inc. |
CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
|
|
WO2025126102A1
(en)
|
2023-12-12 |
2025-06-19 |
Janssen Biotech, Inc. |
Enpp3 × cd3 bispecific antibodies and use thereof
|
|
WO2025133707A1
(en)
|
2023-12-19 |
2025-06-26 |
Vectory Therapeutics B.V. |
Anti-tdp-43 antibodies and uses thereof
|
|
WO2025133694A1
(en)
|
2023-12-20 |
2025-06-26 |
argenx BV |
Fcrn/hsa-binding molecules and methods of use
|
|
GB202319605D0
(en)
|
2023-12-20 |
2024-01-31 |
argenx BV |
Monovalent binding molecules and methods of use
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
TW202547867A
(zh)
|
2024-01-16 |
2025-12-16 |
美商健生生物科技公司 |
使用阿米維單抗治療結腸直腸癌
|
|
WO2025158277A1
(en)
|
2024-01-22 |
2025-07-31 |
Janssen Biotech, Inc. |
Use of amivantamab to treat head and neck cancer
|
|
WO2025166040A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof
|
|
WO2025166042A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
|
WO2025166077A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
Compositions comprising progranulin and uses thereof
|
|
WO2025166045A1
(en)
|
2024-01-31 |
2025-08-07 |
Alector Llc |
β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF
|
|
WO2025191459A1
(en)
|
2024-03-11 |
2025-09-18 |
Janssen Biotech, Inc. |
Use of bispecific anti-egfr/c-met antibodies to treat solid tumors
|
|
WO2025199243A1
(en)
|
2024-03-20 |
2025-09-25 |
Regeneron Pharmaceuticals, Inc. |
Trivalent multispecific binding molecules and methods of use thereof
|
|
WO2025221728A2
(en)
|
2024-04-15 |
2025-10-23 |
Janssen Biotech, Inc. |
Ltbr binding molecules and uses thereof
|
|
WO2025226541A2
(en)
|
2024-04-26 |
2025-10-30 |
Janssen Biotech, Inc. |
Klk2xcd3 antibody and an anti-cancer agent for treating prostate cancer
|
|
WO2025229206A1
(en)
|
2024-05-03 |
2025-11-06 |
argenx BV |
Monovalent anti-iga binding molecules and methods of use
|
|
WO2025233825A1
(en)
|
2024-05-06 |
2025-11-13 |
Janssen Pharmaceutica Nv |
Enrichment of cells expressing a bird linker
|
|
WO2025240335A1
(en)
|
2024-05-13 |
2025-11-20 |
Regeneron Pharmaceuticals, Inc. |
Fgfr3 binding molecules and methods of use thereof
|
|
WO2025243243A1
(en)
|
2024-05-24 |
2025-11-27 |
Janssen Biotech, Inc. |
Bispecific antibody targeting emr2 (cd312) and the t-cell receptor trbv19
|
|
US20250361309A1
(en)
|
2024-05-24 |
2025-11-27 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il12 receptor agonists
|
|
WO2025255452A2
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Antigen-binding molecules that bind to aav particles and uses thereof
|
|
WO2025255480A1
(en)
|
2024-06-07 |
2025-12-11 |
Regeneron Pharmaceuticals, Inc. |
Tetravalent multispecific binding molecules and methods of use thereof
|
|
US20260055171A1
(en)
|
2024-06-11 |
2026-02-26 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonists and methods of use thereof
|
|
WO2025264572A1
(en)
|
2024-06-17 |
2025-12-26 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
|
US20260078179A1
(en)
|
2024-07-18 |
2026-03-19 |
Novarock Biotherapeutics, Ltd. |
Cdh17 antibodies and uses thereof
|
|
WO2026025058A1
(en)
|
2024-07-25 |
2026-01-29 |
Regeneron Pharmaceuticals, Inc. |
Aav viral particles retargeted to egfr-expressing cancer cells
|
|
WO2026035888A1
(en)
|
2024-08-06 |
2026-02-12 |
Janssen Biotech, Inc. |
Methods and compositions for modulating beta chain mediated immunity
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026038160A1
(en)
|
2024-08-13 |
2026-02-19 |
Janssen Biotech, Inc. |
Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
|
|
CA3278557A1
(en)
|
2024-08-13 |
2026-03-01 |
Janssen Biotech, Inc. |
Methods for reducing dermatologic adverse events in patients treated with egfr/met bispecific antibodies
|
|
WO2026039420A1
(en)
|
2024-08-13 |
2026-02-19 |
Janssen Biotech, Inc. |
Bispecific antibody targeting hk2 and cd3 for the treatment of prostate cancer
|
|
WO2026039791A1
(en)
|
2024-08-16 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted split il2 receptor agonists
|
|
WO2026042017A1
(en)
|
2024-08-19 |
2026-02-26 |
Janssen Biotech, Inc. |
Amivantamab in combination with lazertinib for the treatment of non-small cell lung cancer (nsclc)
|
|
WO2026058155A1
(en)
|
2024-09-11 |
2026-03-19 |
Novartis Ag |
Antibodies targeting il-31
|
|
WO2026075989A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Engineered igg molecules and methods of use thereof
|
|
WO2026076013A1
(en)
|
2024-10-01 |
2026-04-09 |
Regeneron Pharmaceuticals, Inc. |
Tumor-targeted il2 receptor agonists and multispecific t-cell engagers
|
|
WO2026078067A1
(en)
|
2024-10-08 |
2026-04-16 |
Novimmune Sa |
Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
|
|
WO2026078647A1
(en)
|
2024-10-11 |
2026-04-16 |
Janssen Biotech, Inc. |
Combination of trispecific antibody targeting bcma, gprc5d and cd3, and pomalidomide for the treatment of multiple myeloma
|
|
WO2026078659A1
(en)
|
2024-10-11 |
2026-04-16 |
Janssen Biotech, Inc. |
Combination of trispecific antibody targeting bcma, gprc5d and cd3, and an anti-cd38 antibody for the treatment of multiple myeloma
|